## Appendix B Synovetin OA® Pre-Screening Questionnaire

You and your veterinarian are assessing the suitability of treating your dog with Synovetin  $OA^{\$}$  in one or more arthritic joints. Synovetin  $OA^{\$}$ , a radio-therapeutic treatment, emits ionizing radiation within the joint to relieve pain and inflammation over an extended time period. Your dog's coat and surroundings will not be affected, and the activity will naturally decrease over time. To maintain overall exposure below federally established limits, there will be certain procedures to follow in the period after treatment.

	Initial Information			Revised 9/20
	Owner Name:		Date:	<u> </u>
	Pet Name:		Date:	<u> </u>
	Person Interviewed: Owner	Other		
	Household Member Information	tion		
	Household members:	Sex:		
		Age:		
[.	General Contact Information	l		
Ţ	as defined below the following Person 1			
	Activity and type of contact invol	ved (direct, close	or intermediate):	Duration:

**Direct** activities are <1ft (e.g., carrying the dog where the elbow is in contact or lap sitting where the elbow is directly on the torso). **Close** activities are at 1ft (e.g., feeding, grooming, sleeping, and routine lap-sitting) **Intermediate** activities are at 3ft (e.g., walking, jogging, and officing).

erson 2	
Activity and type of contact involved (direct, close or intermediate):	Duration:
d additional pages for other household members, if necessary.	
Can interactions with children and pregnant women be modified to minimi	ize close contact with the do
	Yes:
If the answer to the above question is yes, describe proposed modifications	3:
Does your dog currently sleep in the same bed with any household membe	rs?
	Yes:No:
If yes, can arrangements be made to avoid this for the duration indic	
Instructions?	Yes:No:* N/A:
If the answer to the above question is yes, describe proposed modifications	S:
Is your pet mobile enough to climb stairs and/or enter and exit a vehicle in	dependently?
	Yes:No: N/A:
If the answer to the above question is no, provide the owner with additional	al strategies.
Does your dog jump up to beds or furniture with family members, or lap si	it?
,	Yes:No:
If yes, can arrangements be made to avoid this for the duration indic	cated on the Release
Instructions (i.e., not lap sit)?	Yes:* No:* N/A:
If the answer to the above question is yes, describe proposed modifications	S:
Does your dog currently sit in very close proximity (i.e., next to your chair	or at your faat) to you for
more than 3 hours per day?	Yes:No:
If yes, can arrangements be made to avoid this for the indicated time	
· · · · · · · · · · · · · · · · · · ·	Yes: No: * N/A:

If the answer to the above question is yes, describe proposed modifications:

Has the owner been provided with an example Rele	ease Instructions sheet? Yes:No:*
Does the owner fully understand the procedure they	y have arranged for their pet?
	Yes:No:*
Are you and your household members able and will for the time frames indicated on the Release Instruc	ling to modify your routine interaction with your petetions?  Yes:No:*
If the answer to the above question is yes, describe	proposed modifications:
*Any "No" checkmark may be contraindicated for the proc proposed dose to pet, or other clinical factors.	cedure. Contraindication is based on owner response
Additional Items Discussed with Animal Owner(s)	Comments
Release Instructions / ALARA considerations:	
Importance of modifying time and distance from pet	:
Sleeping arrangements:	
Added precaution for children and pregnant women:	
What to do if their pet dies or needs medical attention:	
Transport/carrying techniques to minimize contact:	
Other: (such as 1 animal treated per house per year, boarding, traveling, commercial grooming, or tactile treatment)	
By signing below, I acknowledge I fully understand the rad	liation safety aspects associated with Synovetin OA.
Name of Owner or interviewee:	
Signature:	Date:
Name of individual who conducted interview:	
Signature:	Date:

## **Categories of Dog/Owner Distance Behaviors**

Measured Exposure Rate at Release (mR/h @ 1m)	0.45	0.4	0.3	0.2	0.1	0.05
Common Contact	Release Instructions Duration (weeks)			)		
Up to 5 min/day direct contact (e.g. joint to torso) 15 min/day @ 1 ft 4 h/day @ 3 ft e.g., feeding, grooming, petting, dog walking	2	2	2	2	2	2

## If Not Common Contact Distance Behaviors, Select One Below

Measured Exposure Rate at Release (mR/h @ 1m)	0.45	0.4	0.3	0.2	0.1	0.05
Extended Duration Intermediate Contact		Release Instructions Duration (weeks)				
Up to 5 min/day direct contact (e.g. joint to torso) 15 min/day @ 1 ft 12 h/day @ 3 ft e.g., dog rests at the feet of the owner etc.		2	2	2	2	2
Extended Duration Close Contact			3 2	2	2	
Up to 5 min/day direct contact (e.g. joint to torso) 3 h/day @ 1 ft e.g., holding dog in lap or on the couch, extended grooming, etc. 4 h/day @ 3 ft	3 3					2
Prolonged Close and Intermediate Contact						
Up to 5 min/day direct contact (e.g joint to torso) 11 h/day @ 1ft 9 h/day @ 3 ft e.g., dog sleeps in the owner's bed etc.	6	5	4	3	2	2

Use the above table to fill in the duration (number of weeks) in the following Release Instructions. Assess the duration for each household member that has substantial interaction with the dog. Use the greatest duration value (weeks) in the Release Instructions. For example, if the table indicates a duration of 2 weeks for Person #1 and 3 weeks for Person #2, insert 3 weeks in the Release Instructions. Determination of which dog/owner behavior is decided upon owner answers to the Pre-Screening Questionnaire.

## **Appendix C: Synovetin OA Release Instructions**

Releas	se Instructions following Sy	novetin OA	(tin 117m) Canine Ar	rthritis Thera	npy
Dog's	s Name:	Tr	eatment Date:		
Total l	Dose Administered:	mCi	Measured Exposure	Rate:	mR/h at 1m
therap time p time.	dog has been treated with Synbeutic treatment, emits ionizing beriod. Your dog's coat and sometime To maintain overall exposures weeks.	g radiation vurroundings	within the joint to relieve will not be affected, and	pain and inflation pain and the activity v	ammation over an extended will naturally decrease over
✓	Remember to maintain your	exposure a	s low as reasonably achie	evable (ALAR	A).
✓	Do not sleep with the dog o	r hold the do	og in or near your lap.		
✓	Each member of the househ Daily direct contact should dog's treated elbow to the o sitting where the elbow is d	be limited to wner's torso	o <1 minute. <b>Direct</b> active (e.g., carrying the dog v	rities are those	that are <1ft from the
✓	Each member of the househ contact to <u>4</u> hours. Activitilimitations maintained. <b>Clo</b> sitting) and <b>Intermediate</b> a	ies such as v se activities	valking or playing with y are at 1ft (e.g., feeding, g	our dog can cogrooming, slee	ontinue with distance eping, and routine lap-
✓	Minimize the time that child	dren and pre	gnant women spend in cl	lose contact w	ith the dog.
✓	Avoid long term/daily board by air or across any internat parades, etc.). Provide a cop	ional border	rs or very large, organized	d events (prof	_
✓	Minimize use of public tran your dog in its carrier and/o				
✓	Follow up care is recommer care, please inform the proving information here) with any	ider about i			
	Individualized behavior mo		rom Pre-Screening Ques		
After	or dog dies for any reason with expiration of these instruction nt about extended close conta	ns, you may			
Veteri	inarian signature:			Date:	<u></u>
I have questi	e received this information orations.	ally and in w	riting, and I understand i	it. I have had t	the opportunity to ask any
Dog o	owner signature:		Γ	Date:	